Brief: Mesoblast Says Ryoncil Sales For Quarter Increase 60% To $35.1M
09/01/2026 02:18
Jan 9 (Reuters) - Mesoblast Ltd MSB.AX: RYONCIL SALES FOR QUARTER INCREASE 60% TO US$35.1M Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M